|
Volumn 15, Issue 8, 2001, Pages 698-704
|
Pycnogenol® efficacy in the treatment of systemic lupus erythematosus patients
|
Author keywords
Inflammation; Lupus erythematosus; Pycnogenol ; SLE
|
Indexed keywords
C REACTIVE PROTEIN;
DNA ANTIBODY;
DOUBLE STRANDED DNA;
FIBRINOGEN;
PLACEBO;
PROTEIN P56;
PYCNOGENOL;
REACTIVE OXYGEN METABOLITE;
DNA;
FLAVONOID;
IMMUNOLOGICAL ADJUVANT;
PROTEIN KINASE LCK;
PYCNOGENOLS;
ADULT;
AGED;
APOPTOSIS;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
ERYTHROCYTE SEDIMENTATION RATE;
FEMALE;
HUMAN;
LYMPHOCYTE;
MALE;
NEUTROPHIL;
OXIDATIVE STRESS;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT OUTCOME;
HOSPITALIZATION;
IMMUNOLOGY;
METABOLISM;
MIDDLE AGED;
PILOT STUDY;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
AGED;
APOPTOSIS;
BLOOD SEDIMENTATION;
C-REACTIVE PROTEIN;
DNA;
FEMALE;
FIBRINOGEN;
FLAVONOIDS;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK);
LYMPHOCYTES;
MALE;
MIDDLE AGED;
NEUTROPHILS;
PILOT PROJECTS;
REACTIVE OXYGEN SPECIES;
SEVERITY OF ILLNESS INDEX;
|
EID: 0035542914
PISSN: 0951418X
EISSN: None
Source Type: Journal
DOI: 10.1002/ptr.915 Document Type: Article |
Times cited : (13)
|
References (29)
|